Last reviewed · How we verify
AG-920
AG-920 is a prodrug of 2-fluoroadenine that is converted into its active form, which is a nucleoside analog.
AG-920 is a prodrug of 2-fluoroadenine that is converted into its active form, which is a nucleoside analog. Used for Advanced colorectal cancer.
At a glance
| Generic name | AG-920 |
|---|---|
| Also known as | articaine, Articaine Sterile Topical Ophthalmic Solution |
| Sponsor | American Genomics, LLC |
| Drug class | Nucleoside analog |
| Target | Ribonucleotide reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AG-920 works by inhibiting the enzyme ribonucleotide reductase, which is involved in DNA synthesis. This leads to the inhibition of cancer cell growth and proliferation. Additionally, AG-920 has been shown to have immunomodulatory effects, enhancing the body's natural anti-tumor response.
Approved indications
- Advanced colorectal cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution (PHASE3)
- A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution (PHASE3)
- A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population (PHASE3)
- A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution (PHASE3)
- An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |